Lasmiditan - Latest Advances

5-hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice.

Journal: American journal of physiology. Renal physiology

Published: October 08, 2025

Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval.

Journal: Drug research

Published: September 24, 2025

Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.

Journal: Experimental neurology

Published: June 15, 2025

Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription.

Journal: Therapeutic advances in neurological disorders

Published: June 03, 2025

The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group.

Journal: European journal of neurology

Published: May 31, 2025

Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease.

Journal: Clinical and translational medicine

Published: May 26, 2025

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine.

Journal: The Medical letter on drugs and therapeutics

Published: April 22, 2025

Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation.

Journal: American journal of physiology. Cell physiology

Published: March 13, 2025

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice.

Journal: Neurology international

Published: March 11, 2025

The 5-HT1F Receptor Agonist Lasmiditan improves Cognition and Ameliorates Associated Cortico-Hippocampal Pathology in Aging Parkinsonian Mice.

Journal: bioRxiv : the preprint server for biology

Published: March 03, 2025

Real-World Experience of Lasmiditan for the Acute Treatment of Migraine.

Journal: Journal of clinical neurology (Seoul, Korea)

Published: January 07, 2025

The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.

Journal: The journal of headache and pain

Published: December 13, 2024

Filters

5-hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice.

5-hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice.

Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval.

Lasmiditan in Migraine Management: An Advanced Review of Its Pharmacological Paradigm, Clinical Applications, Safety Considerations, Drug Interaction Spectrum, and Regulatory Approval.

Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.

Lasmiditan ameliorates cortico-hippocampal pathology and improves cognition in aging parkinsonian mice.

Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription.

Time-series clustering analysis for treatment pattern of lasmiditan for 2 years from the initial prescription.

The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group.

The Spectrum of Headaches in Moyamoya Angiopathy: From Mechanisms to Management Strategies-A Consensus Review From the NEUROVASC Working Group.

Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease.

Integrative snRNA-seq, molecular docking and dynamics simulations identifies Lasmiditan as drug candidate for Alzheimer's disease.

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine.

A fixed-dose combination of meloxicam and rizatriptan (Symbravo) for migraine.

Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation.

Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation.

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice.

Identifying Factors Associated with the Efficacy of Lasmiditan 50 mg as an Acute Treatment for Migraine Attacks Under Various Dosing Conditions in Real-World Clinical Practice.

The 5-HT1F Receptor Agonist Lasmiditan improves Cognition and Ameliorates Associated Cortico-Hippocampal Pathology in Aging Parkinsonian Mice.

The 5-HT1F Receptor Agonist Lasmiditan improves Cognition and Ameliorates Associated Cortico-Hippocampal Pathology in Aging Parkinsonian Mice.

Real-World Experience of Lasmiditan for the Acute Treatment of Migraine.

Real-World Experience of Lasmiditan for the Acute Treatment of Migraine.

The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.

The dual impact of ictal and interictal burden in migraine: an analysis from the ObserVational survey of the Epidemiology, tReatment, and Care Of MigrainE (OVERCOME) Japan second study.